Post-liver transplant hepatitis B prophylaxis: The role of oral nucleos(t)ide analogues

Current Opinion in Organ Transplantation

Volumn 14, Issue 3, 2009, Pages 225-230

  Patterson, Scott J ^a   Angus, Peter W ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

Hepatitis B; Liver transplantation; Prophylaxis; Recurrence

Indexed keywords

ADEFOVIR DIPIVOXIL; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; NUCLEOSIDE; NUCLEOTIDE; PHOSPHONIC ACID DERIVATIVE;

ADD ON THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST CONTROL; CREATININE BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; INFECTION PREVENTION; KIDNEY DISEASE; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; RECURRENT INFECTION; REVIEW; SIDE EFFECT; VIRUS INHIBITION; VIRUS REPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; GRAFT SURVIVAL; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; TREATMENT OUTCOME;

ADENINE; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; GUANINE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; INJECTIONS, INTRAMUSCULAR; LAMIVUDINE; LIVER TRANSPLANTATION; NUCLEOSIDES; NUCLEOTIDES; PHOSPHONIC ACIDS; RECURRENCE; TREATMENT OUTCOME;

EID: 67651040834     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832b1f32     Document Type: Review

References (46)

1. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337:813-815.
2. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:1842-1847. (Pubitemid 23360483)
3. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:1212-1215. (Pubitemid 26361609)
4. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585-589. (Pubitemid 28363690)
5. Dan Y, Wai C, Yeoh K, et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost effectiveness analysis. Liver Transpl 2006; 12:736-746.
6. Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl 2008; 14 (Suppl 2):S15-S22.
7. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61:1358-1364. (Pubitemid 26152826)
8. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6:429-433. (Pubitemid 30489114)
9. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132:931-937. This paper describes the largest published study of combination HBIG/LAM prophylaxis and demonstrates equivalence of low-dose i.m. HBIG/LAM prophylaxis (4% actuarial recurrence rate at 5 years) with high-dose i.v. HBIG/LAM. (Pubitemid 46440868)
10. Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as postliver transplantation hepatitis B prophylaxis. Hepatology 2008; 48:1460-1466. This paper describes the only randomized prospective study of switching to ADV/LAM from i.m. HBIG/LAM in 34 patients at least 12 months post-liver transplant. No recurrence was found in either group.
11. Ferretti G, Merli M, Ginanni Corradini S, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 2004; 36:535-538. (Pubitemid 38534313)
12. Karademir S, Astarcioglu H, Akarsu M, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006; 38:579-583.
13. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12:253-258. (Pubitemid 43273784)
14. Hussain M, Soldevila-Pico C, Emre S, et al. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl 2007; 13:1137-1144. (Pubitemid 47305032)
15. Freshwater DA, Dudley T, Cane P, et al. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008; 85:1105-1111. (Pubitemid 351590187)
16. Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6:434-439. (Pubitemid 30489115)
17. Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34:888-894. (Pubitemid 32595189)
18. Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13:374-381.
19. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38:811-817. (Pubitemid 36613348)
20. Buti M, Mas A, Prieto M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84:650-654. (Pubitemid 47429048)
21. Mutimer D, Pillay D, Dragon E, et al. High pretreatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30:715-721. (Pubitemid 29151915)
22. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424-432. (Pubitemid 32119032)
23. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696. (Pubitemid 36337972)
24. Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34:895-902. (Pubitemid 32595190)
25. Rosenau J, Tillmann HL, Bahr MJ, et al. Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation. Transplant Proc 2001; 33:3637-3638. (Pubitemid 34042710)
26. Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001; 72:1381-1385. (Pubitemid 33015762)
27. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536. (Pubitemid 41096641)
28. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45:1056-1075. (Pubitemid 46646501)
29. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254-265. (Pubitemid 47171942)
30. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
31. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133:1445-1451. This study of 145 patients demonstrates the efficacy and safety of ongoing combination ADV/LAM therapy at the onset of LAM-R. (Pubitemid 350047463)
32. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48:728-735. This paper describes the only study of combination ADV/LAM therapy in LAM-naïve patients. ADV/LAM was modestly superior to LAM monotherapy in biochemical and virological outcomes; however, the rate of virological breakthrough was higher (19% at 2 years) than might be expected from the results of ADV/LAM in LAM-R patients.
33. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751. (Pubitemid 44958517)
34. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90. (Pubitemid 38040726)
35. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44:283-290. (Pubitemid 43069209)
36. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance [abstract]. Hepatol Int 2008; 2:s76.
37. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
38. Lai CL, Gane E, Liaw Y-F, et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first year results from the International Phase III Globe Trial [abstract]. Hepatology 2005; 42 (S1):748A.
39. Snow-Lampart A, Chappell BJ, Curtis M, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir 300 mg QD [abstract]. Hepatology 2008; 48 (Suppl 4):745A.
40. van der Poorten D, Prakoso E, Khoo TL, et al. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol 2007; 22:1500-1505. (Pubitemid 47274596)
41. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and postliver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13:349-360. (Pubitemid 46444463)
42. Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52:2497-2500. (Pubitemid 47373893)
43. Lo CM, Liu CL, Lau GK, et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11:807-813.
44. Nath DS, Kalis A, Nelson S, et al. Hepatitis B prophylaxis postliver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20:206-210.
45. Angus PW, Strasser SI, Patterson SJ, et al. A randomized study to assess the safety and efficacy of adefovir dipivoxil substitution for Hepatitis B Immune Globulin in liver transplantation patients receiving long-term low dose IM HBIG and lamivudine prophylaxis [abstract]. Hepatology 2007; 46:238A.
46. Xi Z, Xia Q, Zhang J, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation [abstract]. Hepatol Int 2008; 2:s71.